Rodman & Renshaw Initiates Coverage On Monopar Therapeutics With Buy Rating, Announces Price Target of $50
Rodman & Renshaw Initiates Coverage On Monopar Therapeutics With Buy Rating, Announces Price Target of $50
Rodman & Renshaw啓動對monopar therapeutics的買入評級，宣佈目標價爲$50
Rodman & Renshaw analyst Elemer Piros initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $50.
Rodman & Renshaw 分析師Elemer Piros發起對monopar therapeutics（納斯達克：MNPR）的覆蓋，給予買入評級，並宣佈目標價爲50美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間